185 related articles for article (PubMed ID: 28508195)
1. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.
Okada R; Shimada H; Otsuka Y; Tsuchiya M; Ishii J; Katagiri T; Maeda T; Kubota Y; Nemoto T; Kaneko H
Surg Today; 2017 Dec; 47(12):1492-1499. PubMed ID: 28508195
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
[TBL] [Abstract][Full Text] [Related]
5. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
6. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
[TBL] [Abstract][Full Text] [Related]
7. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
8. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma.
Shimada H; Shiratori T; Takeda A; Matsushita K; Okazumi S; Akutsu Y; Matsubara H; Nomura F; Ochiai T
World J Surg; 2009 Feb; 33(2):272-7. PubMed ID: 19052812
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.
Kato Y; Takahashi S; Gotohda N; Konishi M
J Gastrointest Surg; 2016 Aug; 20(8):1435-43. PubMed ID: 27250990
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
[TBL] [Abstract][Full Text] [Related]
11. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
12. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma.
Yamazaki Y; Chiba I; Ishikawa M; Satoh C; Notani K; Ohiro Y; Totsuka Y; Mizuno S; Kitagawa Y
Odontology; 2008 Jul; 96(1):32-7. PubMed ID: 18661202
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.
Blanchard P; Quero L; Pacault V; Schlageter MH; Baruch-Hennequin V; Hennequin C
BMC Cancer; 2012 Mar; 12():119. PubMed ID: 22448886
[TBL] [Abstract][Full Text] [Related]
14. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival.
Shiota G; Ishida M; Noguchi N; Oyama K; Takano Y; Okubo M; Katayama S; Tomie Y; Harada K; Hori K; Ashida K; Kishimoto Y; Hosoda A; Suou T; Kanbe T; Tanaka K; Nosaka K; Tanida O; Kojo H; Miura K; Ito H; Kaibara N; Kawasaki H
Dig Dis Sci; 2000 Jan; 45(1):122-8. PubMed ID: 10695624
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
16. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of preoperative C-reactive protein/albumin ratio in patients with resected extrahepatic bile duct cancer.
Song DH; Cho IK; Shin DW; Lee JC; Cho JY; Yoon YS; Hwang JH; Han HS; Kim J
Surg Today; 2021 Jun; 51(6):978-985. PubMed ID: 33387024
[TBL] [Abstract][Full Text] [Related]
18. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibodies in correlation to other biological parameters of breast cancer.
Sangrajrang S; Arpornwirat W; Cheirsilpa A; Thisuphakorn P; Kalalak A; Sornprom A; Soussi T
Cancer Detect Prev; 2003; 27(3):182-6. PubMed ID: 12787724
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
Tang X; Zhang J; Chen Y; Lan Z; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
